Nasal Spray Reverses Brain Aging in Animal Models, Texas A&M Team Reports

Researchers at Texas A&M’s Naresh K. Vashisht College of Medicine report a two-dose intranasal therapy that sharply reduced chronic brain inflammation and restored memory function in aging animal models, with effects appearing within weeks and persisting for months. The treatment targets ‘neuroinflammaging’ — the low-grade, persistent inflammation in the brain’s memory center long assumed to be an unavoidable part of getting older. Results were published in the Journal of Extracellular Vesicles (DOI: 10.1002/jev2.70232).

The mechanism relies on extracellular vesicles carrying microRNAs, delivered nasally so they bypass the blood-brain barrier and reach brain tissue directly. Once absorbed by resident immune cells, the microRNAs suppress inflammatory pathways known to drive aging-related decline — notably the NLRP3 inflammasome and cGAS–STING signaling — while recharging neuronal mitochondria and reducing oxidative stress. Treated models performed markedly better on object-recognition and environmental-change tests than controls, and the team reports consistent results across both sexes.

The work is early-stage and confined to animal models, but the researchers have filed a U.S. patent and frame the approach as a potential non-invasive alternative to surgery or long-term medication for cognitive decline, stroke recovery, and dementia. That framing carries weight given projections that U.S. dementia cases will roughly double to about one million per year by 2060 — a trend the lead investigator argues demands new interventions and supportive policy. Human trials would be the necessary next step before any of these claims translate to people.